Conference
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
Authors
Gettinger SN; Shepherd FA; Antonia SJ; Brahmer JR; Chow LQM; Juergens RA; Borghaei H; Shen Y; Harbison C; Alaparthy S
Volume
32
Pagination
pp. 8024-8024
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2014
DOI
10.1200/jco.2014.32.15_suppl.8024
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X